Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?

Raul C. Urtasun; C. Norman Coleman; Todd H. Wasserman; T. L. Phillips

doi:10.1016/0360-3016(84)90530-3

Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?

Raul C. Urtasun, C. Norman Coleman, Todd H. Wasserman, T. L. Phillips

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.

Original language	English (US)
Pages (from-to)	1691-1696
Number of pages	6
Journal	International journal of radiation oncology, biology, physics
Volume	10
Issue number	9
DOIs	https://doi.org/10.1016/0360-3016(84)90530-3
State	Published - Sep 1984
Externally published	Yes

Keywords

Clinical trials
Radioprotectors
Radiosensitizers

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/0360-3016(84)90530-3

Cite this

@article{35594b101ab643bb887a9ac755b697d2,

title = "Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?",

abstract = "Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.",

keywords = "Clinical trials, Radioprotectors, Radiosensitizers",

author = "Urtasun, {Raul C.} and Coleman, {C. Norman} and Wasserman, {Todd H.} and Phillips, {T. L.}",

note = "Funding Information: Reprint request to: R. C. Urtasun, M.D., Cross Cancer Institute, I 1560 University Avenue. Edmonton, Alberta, T6G IZ2. Canada. Acknowledgetnents-This work was supported by Grant #5236, Alberta Heritage Savings and Trust Fund, Applied Research",

year = "1984",

month = sep,

doi = "10.1016/0360-3016(84)90530-3",

language = "English (US)",

volume = "10",

pages = "1691--1696",

journal = "International journal of radiation oncology, biology, physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Clinical trials with hypoxic cell sensitizers

T2 - Time to retrench or time to push forward?

AU - Urtasun, Raul C.

AU - Coleman, C. Norman

AU - Wasserman, Todd H.

AU - Phillips, T. L.

N1 - Funding Information: Reprint request to: R. C. Urtasun, M.D., Cross Cancer Institute, I 1560 University Avenue. Edmonton, Alberta, T6G IZ2. Canada. Acknowledgetnents-This work was supported by Grant #5236, Alberta Heritage Savings and Trust Fund, Applied Research

PY - 1984/9

Y1 - 1984/9

N2 - Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.

AB - Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.

KW - Clinical trials

KW - Radioprotectors

KW - Radiosensitizers

UR - http://www.scopus.com/inward/record.url?scp=0021205184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021205184&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(84)90530-3

DO - 10.1016/0360-3016(84)90530-3

M3 - Article

C2 - 6237083

AN - SCOPUS:0021205184

SN - 0360-3016

VL - 10

SP - 1691

EP - 1696

JO - International journal of radiation oncology, biology, physics

JF - International journal of radiation oncology, biology, physics

IS - 9

ER -

Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this